Nohla Therapeutics
2015
FOUNDED
PRIVATE
STATUS
41-50
EMPLOYEES
Series B
LATEST DEAL TYPE
$56M
LATEST DEAL AMOUNT
12
INVESTORS
Description
Developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases. The company's lead candidate, is an expanded progenitor cell therapy that provides the functional support of bone marrow in response to each patient's unique blood-production needs, without any requirement for HLA matching.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 1600 Fairview Avenue East
- Suite 100
- Seattle, WA 98102
- United States
+1 (206) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Nohla Therapeutics’s full profile, request a free trial.
Nohla Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 12-Jul-2018 | $56M | 00000 | Completed | Clinical Trials - Phase 2 | |
| 3. Grant | 28-Sep-2017 | 00.00 | 000.00 | Completed | Startup | |
| 2. Early Stage VC (Series A) | 29-Nov-2016 | $43.5M | $64.5M | 00000 | Completed | Startup |
| 1. Corporate | 24-Dec-2015 | $21M | $21M | Completed | Startup |
Nohla Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A1 | 000,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
Nohla Therapeutics Competitors (28)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Immatics | Venture Capital-Backed | Tübingen, Germany | 000 | 00000 | 00000000000 | 00000 |
| 00 00000000 | Venture Capital-Backed | Glasgow, United Kingdom | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000000 | Formerly VC-backed | Munich, Germany | 000.00 | 000000&0 | 000.00 | |
| 00000 0000000000 | Formerly VC-backed | Miramar, FL | 00 | 00000 | 000000&0 | 00000 |
Nohla Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Alexandria Venture Investments | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | ||
| AML Biotech Partners | Other | Minority | 000 0000 | 000000 0 | ||
| Celgene | Corporation | Minority | 000 0000 | 000000 0 | ||
| Fidelity Management & Research | Asset Manager | Minority | 000 0000 | 000000 0 | ||
| Premier Partners | Asset Manager | Minority | 000 0000 | 000000 0 |
Nohla Therapeutics Executive Team (10)
5 Former Executives
You’re viewing 5 of 10 executives. Get the full list »Nohla Therapeutics Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Brian Daniels MD | 5AM Ventures | Board Member | 000 0000 | |
| Kathleen Fanning | Nohla Therapeutics | President, Chief Executive Officer & Board Member | 000 0000 | |
| Lawrence Gozlan | Nohla Therapeutics | Board Member | 000 0000 | |
| Michael Sistenich | Nohla Therapeutics | Non-Executive Board of Directors | 000 0000 | |
| Steven Gillis Ph.D | ARCH Venture Partners | Chairman | 000 0000 |
2 Former Board Members
You’re viewing 5 of 7 board members. Get the full list »